Search for 'Provider:Annals of Oncology,'

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(3):423-9. , Formato Vancouver: Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9.

Place Hold on Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(8):1573-9. , Formato Vancouver: Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9.

Place Hold on Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

By Grávalos Castro, Cristina. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . ;26(3):535-41. , Formato Vancouver: Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015 Mar;26(3):535-41.

Place Hold on Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . 26(9):1987-93. , Formato Vancouver: Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep; 26(9):1987-93.

Place Hold on Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology, 2014 . 25(11):2173-8. , Formato Vancouver: Aparicio J, Maroto P, García Del Muro X, Sánchez Muñoz A, Gumà J, Margelí M et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014 Nov;25(11):2173-8.

Place Hold on Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

By Brandariz Castelo, José Antonio | Hitt Sabag, Ricardo. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2014 . 25(1):216–225. , Formato Vancouver: Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A et al. Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25.

Place Hold on A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

By Castellano, Daniel. Annals of Oncology, 2013 . 24(9):2409-14. , Formato Vancouver: Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013 Sep;24(9):2409-14.

Place Hold on Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

By Manso Sánchez, Luis. Annals of oncology: official journal of the European Society for Medical Oncology, 2013 . 24(1):109-16. , Formato Vancouver: Awada A, Dirix L, Manso Sánchez L, Xu B, Luu T, Diéras V et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013 Jan;24(1):109-16.

Place Hold on Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

By Cortés-Funes Castro, Hernán | Hitt Sabag, Ricardo. Annals of Oncology, 2012 . 23(4):1016-22. , Formato Vancouver: Hitt R, Irigoyen A, Cortés-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernández JJ, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012 Apr;23(4):1016-22.

Place Hold on Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

By Cortés-Funes Castro, Hernán. Annals of Oncology, 2011 . 22(3):595-602. , Formato Vancouver: Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22(3):595-602.

Place Hold on First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

By Hitt Sabag, Ricardo. Annals of Oncology, 2011 . 22(5):1078-1087. , Formato Vancouver: Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22(5):1078-87.

Place Hold on Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

By Castellano, Daniel. Annals of Oncology, 2011 . 22(12):2646-2653. , Formato Vancouver: Bellmunt J, González Larriba JL, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646-53.

Place Hold on Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors

By Castellano, Daniel | Hitt Sabag, Ricardo | Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Hitt Sabag, Ricardo | Colomer, R.. Annals of Oncology, 2003 . 14(5):783-787 , Formato Vancouver: Castellano D, Hitt R, Ciruelos E, Cortés-Funes H, Colomer R. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003 May;14(5):783-7.

Place Hold on Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors